Cargando…

Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma

Double-hit lymphoma (DHL) and double-expressor lymphoma (DEL) are aggressive forms of lymphoma that require better treatments to improve patient outcomes. CKD-581 is a new histone deacetylase (HDAC) inhibitor that exhibited a better safety profile in clinical trials compared to other HDAC inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Soo Jin, Kim, U Ji, Yoo, Hae Yong, Choi, Yong June, Kang, Keon Wook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352247/ https://www.ncbi.nlm.nih.gov/pubmed/32575557 http://dx.doi.org/10.3390/ijms21124377

Ejemplares similares

CKD-581 Downregulates Wnt/β-Catenin Pathway by DACT3 Induction in Hematologic Malignancy
por: Kim, Soo Jin, et al.
Publicado: (2022)

The histone deacetylase inhibitor panobinostat is a potent antitumor agent in canine diffuse large B-cell lymphoma
por: Dias, Joana N.R., et al.
Publicado: (2018)

Expression of Histone Deacetylases in Diffuse Large B-cell Lymphoma and Its Clinical Significance
por: Lee, Sung Hak, et al.
Publicado: (2014)

A novel histone deacetylase inhibitor, CKD5, has potent anti-cancer effects in glioblastoma
por: Choi, Seung Ah, et al.
Publicado: (2016)

Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Seok Jin, et al.
Publicado: (2011)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

Increased histone deacetylase 6 expression serves as a favorable prognostic factor for diffuse large B-cell lymphoma
por: Lin, Xiao-Ji, et al.
Publicado: (2017)

Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps
por: Fan, Wenli, et al.
Publicado: (2021)

Single‐cell profiling‐guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma
por: Wang, Luqiao, et al.
Publicado: (2022)

Single‐cell profiling guided combination therapy of c‐Fos and histone deacetylase inhibitors in diffuse large B‐cell lymphoma
por: Krämer, Oliver H., et al.
Publicado: (2022)

581 Chronic Urticaria and Infections
por: Aguilar, Nadia, et al.
Publicado: (2012)

Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis
por: Park, Jin Kyun, et al.
Publicado: (2020)

CKD-5, a novel pan-histone deacetylase inhibitor, synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma
por: Chang, Young, et al.
Publicado: (2020)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

The effects of a histone deacetylase inhibitor on biological behavior of diffuse large B-cell lymphoma cell lines and insights into the underlying mechanisms
por: Cai, Ying, et al.
Publicado: (2013)

A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors
por: Tula-Sanchez, Ana A, et al.
Publicado: (2013)

Histone Deacetylase Inhibition: An Important Mechanism in the Treatment of Lymphoma
por: Guo, Shan-qi, et al.
Publicado: (2012)

Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma
por: Park, Ha Young, et al.
Publicado: (2016)

SUN-581 An Unusual Presentation of Hypothyroidism
por: Alim, Hussam, et al.
Publicado: (2019)

Paradoxical Regulation of Hypoxia Inducible Factor-1α (HIF-1α) by Histone Deacetylase Inhibitor in Diffuse Large B-Cell Lymphoma
por: Bhalla, Savita, et al.
Publicado: (2013)

Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors
por: Baud, Matthias G J, et al.
Publicado: (2013)

Discovery of indole-3-butyric acid derivatives as potent histone deacetylase inhibitors
por: Chen, Yiming, et al.
Publicado: (2021)

Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro
por: Oh, Bo Ram, et al.
Publicado: (2017)

R-CHOP chemoimmunotherapy followed by autologous transplantation for the treatment of diffuse large B-cell lymphoma
por: Lee, Hong Ghi, et al.
Publicado: (2014)

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019)

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
por: Lu, Guang, et al.
Publicado: (2023)

Therapeutic Potential of CKD-504, a Novel Selective Histone Deacetylase 6 Inhibitor, in a Zebrafish Model of Neuromuscular Junction Disorders
por: Jeong, Hui Su, et al.
Publicado: (2022)

The Sensitivity of Diffuse Large B-Cell Lymphoma Cell Lines to Histone Deacetylase Inhibitor-Induced Apoptosis Is Modulated by BCL-2 Family Protein Activity
por: Thompson, Ryan C., et al.
Publicado: (2013)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Inhibitors of human histone deacetylase with potent activity against the African trypanosome Trypanosoma brucei
por: Kelly, John M., et al.
Publicado: (2012)

Synthetic Routes and Biological Evaluation of Largazole and Its Analogues as Potent Histone Deacetylase Inhibitors
por: Li, Shang, et al.
Publicado: (2011)

Improved early development of porcine cloned embryos by treatment with quisinostat, a potent histone deacetylase inhibitor
por: TAWEECHAIPAISANKUL, Anukul, et al.
Publicado: (2018)

Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells
por: Ding, Ning, et al.
Publicado: (2014)

581. The Epidemiology of Imipenem-Resistant Acinetobacter baumannii Bacteremia in a Pediatric Intensive Care Unit and Carbapenem Use
por: Kim, Dongsub, et al.
Publicado: (2019)

Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues
por: Choi, Jae‐Hoon, et al.
Publicado: (2001)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Therapeutic Comparison of Chemotherapy and Surgery for Early Stage Diffuse Large B-cell Gastric Lymphoma
por: Kim, Soo-Jeong, et al.
Publicado: (2007)

The combination of histone deacetylase inhibitors with immune-stimulating antibodies has potent anti-cancer effects
por: West, Alison C., et al.
Publicado: (2012)

Histone Deacetylase 6 Inhibitor CKD-WID Suppressed Monosodium Urate-Induced Osteoclast Formation by Blocking Calcineurin-NFAT Pathway in RAW 264.7 Cells
por: Kim, Seong-Kyu, et al.
Publicado: (2023)

Histone deacetylase inhibition attenuates hepatic steatosis in rats with experimental Cushing's syndrome
por: Kim, Mina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mr2jd30nofari6v732641lraae